Table 1.

Proteomics-based targets of ASD.

Reference	Matrix	N° of Subjects	Analytical Technique	Proteins Implicated and Pathways
[50] Junaid MA et al., 2004	Brain	8 ASD and 10 controls	2-DE, LC-MS/MS	Glo1 (osteoclastogenesis and ASD etiology)
[51] Broek JA et al., 2014	Brain	prefrontal cortex, 10 ASD and 10 controls; cerebellum, 16 ASD, 17 controls	SRM-MS	VIME, CKB, MAG, MBP, MOG, PLP1, DNM2, STX1A, STXBP1, GFAP, PACSIN1, SYN2, SYT1 (synaptic transmission and energy metabolism)
[52] Wingo et al., 2019	Brain	27 ASD, 76 controls	Large-scale proteome-wide association	VGF, SEPT5, DBI, MAPT, KIAA1045, DLD, ABHD10, VDAC1, NDUFV1, PDHB (cognitive stability)
[53] Corbett et al., 2007	Blood	69 ASD and 35 controls	LC-MS/MS	FHR1, C1Q, FN1, APOB-100 (indirect impact on brain development in ASD)
[54] Ngounou Wetie et al., 2014	Blood	7 ASD and 7 controls	one dimensional gel electrophoresis (1-DE), LC-MS/MS	APOA1, APOA4, PON1 (Lipid metabolism - paraoxonase activity)
[55] Steeb et al., 2014	Blood	30 ASD and 29 controls	Immunoassay, LC-MS/MS	ADIPO, ARMC3, APOA1, APOE, APOC2, BMP6, CHGA, CLC4K, CTGF, EPO, FETUB, GLCE, ICAM1, IL3, IGA, IL16, IL12A, MRRP1, RGPD4, SHBG, PAP, PTPA, RN149, TENA, TLE1, TNF, TF, TRIPB, ZC3HE (Lipid metabolism, cell growth, inflammation)
[56] Yang et al., 2018	Blood	68 ASD and 80 controls	MALDI-TOF MS	APOC1, AFP, CPB2, FAPB1, FGA, PF4, SERPINA5, TAAR6 (lipid metabolism)
[57] Cortelazzo et al., 2016	Blood	30 ASD and 30 controls	2-DE, LC-MS/MS	A1AT, A2M, HPT, FIBB, FIBG, APOA1, APOA4, APOJ, ALBU, IGHA1, IGHAG (acute inflammatory and lipid metabolism)
[58] Feng et al., 2017	Blood	15 ASD and 15 controls	2-DE, Western blot/protein carbonylation and MALDI-TOF	C8A, IGKC (Immune system)
[59] Shen et al., 2018	Blood	30 ASD and 30 controls	Proteo-Miner protein enrichment, iTRAQ, LC-M S/MS	ACTG1, ACTN1, AGT, APOE, CALM1, CALR, C3, C5, EHD3, ENO1, FERMT3, FBLN1, FN1, IGFALS, ITGA2B, MAPRE2, PARVB, SERPINA1, SERPIN4A, THBS1, TLN1, VCL, VCP, VTN (complement system, platelet function, focal adhesions, cytoskeleton, motility and migration and synaptogenesis)
[60] Castagnola et al., 2008	Saliva	27 ASD and 23 controls	LC-MS/MS	HTN1, PRP, STATH (Antimicrobial peptides and central nervous system)
[61] Ngounou Wetie et al., 2015	Saliva	6 ASD and 6 controls	2-DE, LC-MS/MS	AMY1A, AZGP1, CREBBP, CST5, FRAT1, GRTP1, KIF14, ITGA6, HERC1, MRP14, MUC16, PLG, PSP, PIP, TF, ZG16 (immune and inflammation response, lipid metabolism, oxidative stress)
[62] Ngounou Wetie et al., 2015	Saliva	6 ASD and 6 controls	LC-MS/MS	DMBT1, ELANE, HTN1, IGKC, IGHG1, IGLC2, LTF, PIGR, PIP, PRH1, STATH (Inflammation and Immune response)
[63] Suganya et al., 2015	Urine	30 ASD and 30 controls	2-DE, MALDI-TOF MS	IGHG1, KNG1, MASP2 (Inflammation, coagulation and complement system)
[64] Pichitpunpong et al., 2019	lymphoblastoid cell lines	Not available	2-DE, LC-MS/MS, Western blotting	DLD, IDH2, TPT1, ANXA5, CCT5, COX5A, LGALS1, GSTP1, HNRNPA1, PGAM1, TUBB, H3F3C, DBI, AHSG, ERH, CLTA, CALM1, ENO1 (Neurological functions and inflammation)